



## Rapidly advancing pipeline

### Mast cell disorders


DISCOVERY      EARLY STAGE DEVELOPMENT      LATE STAGE DEVELOPMENT      COMMERCIAL



### Solid tumors



### Additional research



ongoing or completed      planned

Updated as of January 8, 2024.

<sup>1</sup>Also approved in the U.S. for adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Approved in Europe (AYVAKYT®) for adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

<sup>2</sup>Stone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib in Greater China.

<sup>3</sup>Approved in the U.S. for adults with indolent SM. Approved in Europe (AYVAKYT) for adults with indolent SM with moderate to severe symptoms inadequately controlled on symptomatic treatment.

<sup>4</sup>Approved in the U.S. for adults with advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). Approved in Europe (AYVAKYT) for adults with ASM, SM-AHN or MCL, after at least one systemic therapy.

GIST = gastrointestinal stromal tumors. SM = systemic mastocytosis.

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

**Not for promotional use.**